🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)5mg → 10mg → 15mg titration — looking for input

5mg → 10mg → 15mg titration — looking for input

MikeKY_noInsulin Thu, Mar 21, 2024 at 9:19 PM 30 replies 2,350 viewsPage 1 of 6
This thread is more than 26 months old. Information may be outdated. Consider searching for more recent discussions.
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Mar 21, 2024 at 9:19 PM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

Four weeks is the pharmacokinetics, not caution. With a one-week half-life you need four to five half-lives to reach steady state, so at two weeks you are dosing on top of a concentration that has not finished rising. Escalating then stacks exposure and you get the side-effect burden of the higher dose before you have seen the benefit of the current one.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

What I actually want to know is why the interval is four weeks rather than two, and whether a slower ladder gets to the same place. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
38 8sean_dublin, hannah_MT, Dr.SportsMedIN and 35 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Mar 21, 2024 at 9:36 PM#2
MikeKY_noInsulin said:
Four weeks is the pharmacokinetics, not caution.

MikeKY_noInsulin has the substance of this right. The condition it depends on is worth stating. Holding longer is the underrated move. A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component tachyphylaxes while the appetite effect persists. Escalating at week two throws that adaptation away.

Last edited: Mar 22, 2024 at 3:36 AM
37 7PharmacoVig_BOS, SurmountFan_IN, PeptideChemSF and 34 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
Mar 21, 2024 at 9:53 PM#3
MikeKY_noInsulin said:
Four weeks is the pharmacokinetics, not caution.

I disagree that the ladder is purely tolerability. The maintenance and regain data cluster at the top doses, so a ladder abandoned halfway leaves you outside the evidence base for the part that matters most — keeping it off.

36 6Dr.NutriCornell, pam_stl, wei_SG and 33 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Mar 21, 2024 at 10:10 PM#4

Taking the question as asked, rather than the general version of it. The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks later. The end point of the ladder is set by tolerability, not by a schedule, and there is no evidence that reaching the top faster produces a better outcome.

35 5tony_orlando, Dr.NephBHM_UK, kim_atl_prep and 32 others
Reply Quote Save Share Report
PeptideSynthNJ
Member
234
1,234
Aug 2024
Princeton, NJ
Mar 21, 2024 at 11:42 PM#5
Dr.ObesityMed said:
A step that is uncomfortable at week two is frequently comfortable at week six with no change in dose, because the gastric-emptying component…

Same pattern here, and in the same order. Nothing to add that would improve it.

Last edited: Mar 22, 2024 at 3:42 AM
34 4Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 31 others
Reply Quote Save Share Report
1236

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register